Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism
NCT07649161
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a key role in how cells make and use energy. The main questions are: Does short term NR treatment increase the NAD+ to NADH ratio in the brain, and does it change other brain energy measures that we can see with a special type of MRI scan called phosphorus 31 MR spectroscopy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Adult
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- June 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dauten Family Center for Bipolar Treatment Innovation · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.